# Veronica Gambillara Fonck

> Veronica Gambillara Fonck is a Switzerland-based bioengineer, company founder and investor. A member of GlycoVaxyn’s executive team before its acquisition by GSK, she co-founded and led LimmaTech Biologics and served as GlycoEra’s founding CEO. She joined Pureos Bioventures as a partner in October 2022 and became chair of MinervaX in November 2024.

- **Role:** Partner at Pureos Bioventures; Chair of the Board at MinervaX
- **Organizations:** Pureos Bioventures, MinervaX, GlycoEra AG (co-founder; former CEO), LimmaTech Biologics (co-founder; former CEO), GlycoVaxyn (former executive team member)
- **Education:** PhD in life sciences, EPFL, Engineering degree, IMD Business School
- **Known for:** Co-founded LimmaTech Biologics and served as CEO., Co-founded GlycoEra and served as CEO from inception until May 2022., Led GlycoEra through a CHF 45 million (US$49 million) Series A announced in November 2021.

## Career timeline

- **2005** — Completed her EPFL doctorate; listed among former PhD students for 2005.
- **2009** — Joined GlycoVaxyn; worked in regulatory affairs and business development.
- **2015** — Helped build GlycoVaxyn ahead of its acquisition by GSK; co-founded LimmaTech Biologics and became CEO.
- **2020** — GlycoEra established, with Gambillara Fonck as co-founder and founding CEO.
- **2021-01** — GlycoEra publicly announced its incorporation and spinout from LimmaTech on January 5.
- **2021-11** — As CEO, announced GlycoEra’s CHF 45 million (US$49 million) Series A on November 5.
- **2022-05** — Ganesh V. Kaundinya succeeded her as GlycoEra president and CEO on May 3.
- **2022-10** — Joined Pureos as partner, effective October 1; joined the MinervaX board in October.
- **2024-11** — MinervaX announced her appointment as board chair on November 14.

## Achievements

- Co-founded LimmaTech Biologics and served as CEO.
- Co-founded GlycoEra and served as CEO from inception until May 2022.
- Led GlycoEra through a CHF 45 million (US$49 million) Series A announced in November 2021.
- Member of the GlycoVaxyn team that helped build the company ahead of GSK’s 2015 acquisition.
- Appointed partner at Pureos effective October 1, 2022.
- Appointed MinervaX board chair in November 2024.

## Latest updates

- **2024-11** — MinervaX announced her appointment as board chair on November 14, following board membership since October 2022.
- **2026-10** — Pureos’s current team page lists her as a partner; MinervaX’s board page lists her as chair. Verified October 15, 2026.

## Links

- LinkedIn: https://www.linkedin.com/in/veronica-gambillara-fonck-80497a21/

---

Profile page: https://yespress.io/veronica-gambillara-fonck
Published by YesPress — https://yespress.io
Last updated: 2026-10-15